Vironexis Biotherapeutics Inc.
Clinical trials sponsored by Vironexis Biotherapeutics Inc., explained in plain language.
-
Gene therapy takes aim at Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study tests a new gene therapy called VNX-202 for people with HER2-positive solid tumors. The therapy uses a harmless virus to deliver instructions that help the body's immune cells attack cancer. The trial has two parts: one for advanced cancers that have stopped responding…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Gene therapy injection takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC